Literature DB >> 33315086

ERCC1 mutations impede DNA damage repair and cause liver and kidney dysfunction in patients.

Katja Apelt1, Susan M White2,3, Hyun Suk Kim4, Jung-Eun Yeo4, Angela Kragten1, Annelotte P Wondergem1, Martin A Rooimans5, Román González-Prieto6, Wouter W Wiegant1, Sebastian Lunke2,7, Daniel Flanagan2, Sarah Pantaleo2, Catherine Quinlan3,8,9, Winita Hardikar3,10,11, Haico van Attikum1, Alfred C O Vertegaal6, Brian T Wilson12,13,14, Rob M F Wolthuis5, Orlando D Schärer4,15, Martijn S Luijsterburg1.   

Abstract

ERCC1-XPF is a multifunctional endonuclease involved in nucleotide excision repair (NER), interstrand cross-link (ICL) repair, and DNA double-strand break (DSB) repair. Only two patients with bi-allelic ERCC1 mutations have been reported, both of whom had features of Cockayne syndrome and died in infancy. Here, we describe two siblings with bi-allelic ERCC1 mutations in their teenage years. Genomic sequencing identified a deletion and a missense variant (R156W) within ERCC1 that disrupts a salt bridge below the XPA-binding pocket. Patient-derived fibroblasts and knock-in epithelial cells carrying the R156W substitution show dramatically reduced protein levels of ERCC1 and XPF. Moreover, mutant ERCC1 weakly interacts with NER and ICL repair proteins, resulting in diminished recruitment to DNA damage. Consequently, patient cells show strongly reduced NER activity and increased chromosome breakage induced by DNA cross-linkers, while DSB repair was relatively normal. We report a new case of ERCC1 deficiency that severely affects NER and considerably impacts ICL repair, which together result in a unique phenotype combining short stature, photosensitivity, and progressive liver and kidney dysfunction.
© 2020 Crown copyright. The government of Australia, Canada, or the UK ("the Crown") owns the copyright interests of authors who are government employees. The Crown Copyright is not transferable.

Entities:  

Year:  2021        PMID: 33315086     DOI: 10.1084/jem.20200622

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  4 in total

Review 1.  Tubular Cell Cycle Response upon AKI: Revising Old and New Paradigms to Identify Novel Targets for CKD Prevention.

Authors:  Letizia De Chiara; Carolina Conte; Giulia Antonelli; Elena Lazzeri
Journal:  Int J Mol Sci       Date:  2021-10-14       Impact factor: 5.923

2.  ZMYM2 restricts 53BP1 at DNA double-strand breaks to favor BRCA1 loading and homologous recombination.

Authors:  Doohyung Lee; Katja Apelt; Seong-Ok Lee; Hsin-Ru Chan; Martijn S Luijsterburg; Justin W C Leung; Kyle M Miller
Journal:  Nucleic Acids Res       Date:  2022-04-22       Impact factor: 19.160

3.  Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients.

Authors:  Peng Cao; Wei Guo; Jun Wang; Sanlan Wu; Yifei Huang; Yang Wang; Yani Liu; Yu Zhang
Journal:  Front Pharmacol       Date:  2022-08-25       Impact factor: 5.988

4.  ERCC1 Overexpression Increases Radioresistance in Colorectal Cancer Cells.

Authors:  Yi-Jung Huang; Ming-Yii Huang; Tian-Lu Cheng; Shih-Hsun Kuo; Chien-Chih Ke; Yi-Ting Chen; Yuan-Chin Hsieh; Jaw-Yuan Wang; Chiu-Min Cheng; Chih-Hung Chuang
Journal:  Cancers (Basel)       Date:  2022-09-30       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.